NLS Careers article

On November 13, the day before the company's Extraordinary General Meeting, it was announced that Mikael Dolsten will not seek election to the Board of Directors as otherwise announced in the notice convening the meeting.

Imagine your job involves meeting with entrepreneurs and researchers who are passionate about developing drugs that could transform or save lives, and realizing you could be part of that future. That is just another “day at the office” for Ester Sklarsky, who has been a principal for the Swedish venture capital firm Sound Bioventures for the past three and a half years.

As part of this process, the company has initiated the statutory consultation required under Swedish employment law regarding a proposed reduction of six positions, which accounts for about 20 percent of its current workforce in Sweden.

Karolinska Institutet (KI) has signed an agreement with the Public Health Agency of Sweden that enables the lending of personnel between the authorities.

Sweden's State Epidemiologist, Magnus Gisslén, resigned in August, stating that his former employer has serious problems, including lack of medical expertise in management. He has also compared the agency to its Danish equivalent, Statens Serum Institute (SSI), where "the management consists of leading medical experts and important research is conducted". NLS asked the Executive Vice President (EVP) of SSI, Tyra Grove Krause, about their management and the importance of working closely with academic partners.

“The goal of our clinical strategy is to further broaden the positioning of vididencel in the AML treatment landscape and in CML as a new indication. The execution of this clinical development plan requires operational focus, and we will therefore reduce our R&D activities to what is required to support our clinical programs," says Mendus CEO Erik Manting.